Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis.

Nadali, Gianpaolo; Vinante, Fabrizio; Ambrosetti, Achille; Todeschini, Giuseppe; Veneri, Dino; Zanotti, Roberta; Meneghini, Vittorio; Ricetti, M. M.; Benedetti, Fabio; Vassanelli, A.

doi:10.1200/jco.1994.12.4.793

Cited by 98 publications

(63 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study and those presented by others (Gruss et al, 1993;Nadali et al, 1994;Seymour et al, 1997) clearly indicate the possible use of certain biological markers along with established clinical and laboratory variables for more appropriate prognostic risk assignment in HD patients.…”

Section: Discussionsupporting

confidence: 76%

“…Therefore, the association between TNF and its soluble receptors' plasma levels and disease extent and burden suggests the possibility that their plasma levels in HD patients reflect the neoplastic component of the disease. This suggestion is supported by the observations of others who found elevated levels of p55 TNF receptor and soluble CD30 in HD patients (Gruss et al, 1993;Nadali et al, 1994). In addition, the TNF-related ligands may interact with surrounding reactive cells, particularly T cells, which in turn may enhance the production of cytokines and receptors in a paracrine fashion Bazzoni and Beutler, 1996).…”

Section: Discussionmentioning

confidence: 60%

“…H-RS cells have been reported to produce several cytokines and receptors, including those of the TNF ligand receptor family members (Nadali et al, 1994;. Therefore, the association between TNF and its soluble receptors' plasma levels and disease extent and burden suggests the possibility that their plasma levels in HD patients reflect the neoplastic component of the disease.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients

Warzocha

Bienvenu²,

Ribeiro³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary A prospective study was performed to assess the use of plasma measurement of tumour necrosis factor (TNF), lymphotoxin alpha (LTax) and their soluble receptors (p55 and p75) for prognostic risk assignment in 61 patients with Hodgkin's disease. Plasma levels of TNF, p55 and p75, but not of LTax, were higher in Hodgkin's disease patients than in healthy controls. Plasma levels of TNF, p55 and p75 were associated with several prognostic factors for Hodgkin's disease, including those related to the host (age, performance status) and to the tumour (disease stage, extranodal site involvement, bulky tumour, serum levels of LDH and ,B2-microglobulin, histology). Elevated plasma levels of TNF, p55 and p75 were also associated with several parameters reflecting an immune activation, including the presence of B symptoms, elevated serum levels of gammaglobulins, alkaline phosphatase and fibrinogen, as well as peripheral monocytosis, anaemia and low serum albumin levels. Finally, elevated TNF ligand receptor plasma markers were associated with a lower incidence of complete response to therapy and predicted shorter free-from-progression survival and overall survival of the patients. These results indicate that the plasma levels of TNF and its soluble receptors correlate with clinical features and outcome of patients with Hodgkin's disease.

show abstract

Section: Discussionsupporting

confidence: 76%

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients

Warzocha

Bienvenu²,

Ribeiro³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…This type of cleavage is common in type I membrane proteins including other immunotherapy targets such as CD25 (23) and the erb-B2 protein (24). The level of soluble CD30 is elevated according to the progression status of the lymphoma (3,19,25,26). The cleavage site(s) of CD30 has not been precisely identified, but it is assumed to be close to the plasma membrane, by analogy with other soluble receptors (20) and by studies using various deletion mutants of CD30 (22).…”

Section: Fig 1 Transformation Assay Of Flag͞ha-tagged and Untagged mentioning

confidence: 99%

Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy

Nagata

Ise²,

Onda³

et al. 2005

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

10.1073͞pnas.0504604102), the authors note that Eq. 1 was incorrectly given as P ϭ f ssͩ ͩ1 ϩ m ͪ ϩ Dͩ 2 ϩ m ͪͪ both in the text and in Fig. 2. The correct equation is as follows:The corrected figure and its legend appear below. The error does not affect the conclusions of the article. Fig. 2.Comprehensive characterization of the promoter library. Several orthogonal metrics were used to characterize the promoter library and ensure the consistent behavior of all its members for various genes and culturing conditions. We show here three metrics that were chosen for quantifying transcriptional of the promoters: (i) the dynamics of GFP production based on fluorescence, (ii) measurement of the relative mRNA transcript levels in the cultures, and (iii) testing of the MIC for chloramphenicol in an additional library of constructs where the promoter drove the expression of chloramphenicol acetyltransferase. The overall strong correlation between the various metrics suggests a broad-range utility of the promoter library for a variety of genes and conditions.

show abstract

“…36 Levels of soluble CD30 are also elevated in ALCL, 37 and may explain the B symptoms that patients with the disease experience. 38,39 Furthermore, elevated soluble CD30 is thought to protect against CD30 ligand-mediated cell death, and may correlate with a poor prognosis. 36 Patients with ALCL also may have high serum levels of CA125 and IL-6, 40 and galectin-3.…”

Section: Discussionmentioning

confidence: 99%

Ki-1 anaplastic large-cell lymphoma occurring at the site of ileocolonic anastomosis in a patient treated surgically for colonic adenocarcinoma: Case report and review of the literature

Cooperberg

Fiedler

2001

Annals of Diagnostic Pathology

View full text Add to dashboard Cite

Systemic anaplastic large-cell lymphoma is an uncommon type of non-Hodgkin lymphoma characterized by strong expression of the Ki-1 (CD30) antigen. Gastrointestinal involvement typically is less common than in other types of non-Hodgkin's lymphoma. We report a case of CD30-positive anaplastic large-cell lymphoma occurring at the site of colonic anastomosis in an elderly patient who had been treated for colonic adenocarcinoma by right hemicolectomy 10 years previously. The lymphoma was a 2-cm mass composed of large, atypical cells infiltrating the mucosa, submucosa, and muscularis propria. Immunoperoxidase stain was strongly positive for Ki-1, and negative for LeuM1, L26, UCHL1, EMA, and cytokeratin. There have been numerous reports of unusual extranodal presentations of systemic anaplastic large-cell lymphoma; the only previously reported case involving the colon, however, occurred in the context of ulcerative colitis. Anastomotic recurrence is a relatively common complication of surgical therapy for adenocarcinoma, but the recurrent tumors are invariably adenocarcinomas. We are aware of no cases of lymphoma of any type occurring at the site of anastomosis after resection for adenocarcinoma.

show abstract

Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis.

Abstract: sCD30 in HD at presentation strictly correlates with clinical features. Serum levels greater than 100 U/mL at diagnosis entail a significantly higher risk of treatment failure, a factor that is independent of other prognostic parameters.

Cited by 98 publications

References 13 publications

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients

Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy

Ki-1 anaplastic large-cell lymphoma occurring at the site of ileocolonic anastomosis in a patient treated surgically for colonic adenocarcinoma: Case report and review of the literature

Contact Info

Product

Resources

About